Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Entrectinib in Hepatic Impairment
NCT04226833Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of entrectinib in solid tumor and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration of Entrectinib, Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity of Entrectinib and 12 more. Started Feb 2020; status: completed.
02
Drugs
entrectinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04226833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226833.